[PDF] Top 20 Conquista y colonización de Nicaragua. 1a.pdf
Has 10000 "Conquista y colonización de Nicaragua. 1a.pdf" found on our website. Below are the top 20 most common "Conquista y colonización de Nicaragua. 1a.pdf".
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
... IFN transcriptional signature included genes which have previously been shown to correlate with the clinical effects of treatment in RRMS ...RRMS patients, showed that pa- tients with lower ... See full document
8
Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis
... therapeutic response to the different forms of IFNβ on the annualized relapse rate and EDSS progres- sion, except the work of Etemadifar et ...clinical response to IFNβ in male ...clinical response ... See full document
5
Early stage and long term treatment of multiple sclerosis with interferon-β
... Abstract: Multiple sclerosis (MS) affects young adults during the most productive years of their lives, and until recently many neurologists were limited to treating symptoms and attacks without any ability ... See full document
34
A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis
... by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) trial and the EVidence of Interferon Dose-response: Euro- pean North American Comparative Efficacy ... See full document
10
Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
... Abstract: Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive (10%–15%) or relapsing-remitting (85%–90%) ...The patients experience an acute ... See full document
6
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
... voice response or web system and stratified by site) into three treatment arms (1:1:1) as follows: PEG-IFN beta-1a at a dose of 125 μ g every 2 weeks (PEG-IFN 2w), PEG- IFN ... See full document
470
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
... IFN, interferon; IM intramuscular; IV, intravenous; LFT, liver function tests; mAb; monoclonal antibody; MMP, matrix metalloproteinase; MS, multiple sclerosis; NF-κβ, nuclear factor-kappa β; Nrf2, ... See full document
9
Neopterin production and tryptophan degradation during 24 months therapy with interferon beta 1a in multiple sclerosis patients
... MS patients develop NAbs against IFNb, which interfere with the receptor-mediated functions of IFNb; the clinical rele- vance of NAbs has been the subject of debate because they appear to decrease treatment ... See full document
7
PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
... randomized patients who are administered PEG-IFN beta-1a at a dose of 125 µ g every 2 weeks or 4 weeks after an initial titration phase starting at 63 µ ...involve patients aged 18–65 years ... See full document
66
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart<sup>®</sup> in patients with multiple sclerosis
... Multiple sclerosis (MS) is a chronic, inflammatory, and degenerative disease of the central nervous system with a heterogeneous clinical ...many patients with RRMS develop secondary ... See full document
9
Importance of neutralizing antibody positivity in Tur kish multiple sclerosis patients
... MS patients between May 2008 and October 2009. All patients were routinely attending the Neurology Department of Dokuz Eylul University Hospital, ...Izmir. Patients were receiving one of three ... See full document
17
<p>Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization</p>
... of patients with de novo head- aches following commencement of IFN- β treatment- developed migraines, and the other half developed ten- sion-type headaches ...of patients had episodic headaches ... See full document
9
An Atypical Presentation of Multiple Sclerosis
... Multiple Sclerosis (MS) involves an immune mediated process in which an abnormal response of the body’s immune system is directed against the central nervous system ...(CNS). Multiple ... See full document
18
Emerging oral immunomodulating agents – focus on teriflunomide for the treatment of multiple sclerosis
... Abstract: Treatment for multiple sclerosis (MS), a chronic disease of the central nervous system, has historically relied exclusively on the use of injectable ...for treatment of ...to ... See full document
18
Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis
... (PEG) interferon beta 1a has been approved by the United States Food and Drug Administration (USFDA) as an alternative to interferon beta 1a for multiple sclerosis ... See full document
9
Autoinjector preference among patients with multiple sclerosis: results from a national survey
... All patients were asked 22 questions in the same ...the patients’ own devices to them instead of video ...Then patients answered questions about their satisfaction with the device in ...the ... See full document
7
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
... GA treatment group than in the IFN β -1b 250 µ g group, but in the same way, the incidence of this reactions decreased over the ...in patients treated with IFN β -1b than in those treated with ...to ... See full document
62
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
... of treatment with interferon beta-1a, interferon beta-1b, or GA sometime during the follow-up ...CIS patients who may have received DMT after the follow-up period were not ... See full document
25
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
... in patients with advanced disability and progressive stages of the disease [1, 4, 8, 9, 18, 34, 39], the stage at which spinal cord atrophy is most commonly seen [2, 6, 10, 30, ... See full document
11
The use of natalizumab for multiple sclerosis
... the treatment of relapsing–remitting multiple sclerosis ...preventing multiple sclerosis (MS) lesion accumulation on magnetic resonance imaging, and decreasing the probability of ... See full document
12
Related subjects